Longterm-Evaluation of Vitelene® Against Standard

The purpose of this randomised prospective multicenter longterm study is to evaluate the survival rate of the implant, wear and periprosthetic osteolysis of highly cross-linked polyethylene with and without addition of Vitamin E (UHMWPE-XE vs. UHMWPE-X) in Total Hip Arthroplasty.

Inclusion: * Minimum age: 18 years * Maximum age: 75 years * Indication of cementless THA * Approval of study participation and treatment according to study protocol * Physical and mental willingness of adhering to clinical and radiological follow up Exclusion: * Patient is not able to join follow up * Increased risk of anaesthesia according to the "American Society of Anesthesiology": ASA IV * Tumor disease * Alcohol and drug dependency * Permanent cortisone therapy * Clinical relevant infections * Pregnancy and planned pregnancy * Previous interventions like adjustment-osteotomy, treatment of fractures or THA on affected side * Acute fractures of the affected hip joint * Patients with bone quality, which doesn´t allow a cementless treatment * Requirements of clinical relevant deformities (condition after preoperation or bone fracture, leg length discrepancy \> 30 mm, Offset-reduction about \> 30 mm) * Small acetabular treatments with 28 mm heads * Treatments without using ceramic heads * Treatments which require neck prolonging components